A miRNA Signature Predicts Benefit from Addition of Hypoxia-Modifying Therapy to Radiation Treatment in Invasive Bladder Cancer-Beyond the Abstract – Beyond the Abstract

Organ preservation tri-modality therapy for locally advanced bladder cancer involves transurethral resection of the bladder tumor followed by radiotherapy with a radiosensitizer. The radiosensitizer could be hypoxia-modifying therapy or chemotherapy.¹ Both approaches achieve similar survival benefits, but a predictive biomarker would enable a personalized and optimized choice.¹ Our group develops hypoxia-associated, tumor type-specific gene expression signatures. The signatures are prognostic in multiple cohorts and predict benefits from having hypoxia-modifying therapy with radiotherapy.